Increasing prevalence of cancer is supporting the growth of the global recombinant human endostatin market
North America is expected to lead the global recombinant human endostatin market and this is attributed to the high prevalence of cancer in the region which is creating demand for such therapy. According to a report by the Centers for Disease Control and Prevention (CDC), around 1,633,390 new cancer cases were reported in the U.S. in 2015 and the number is expected to reach 1,735,350 in 2018. Also, an increasing number of clinical trials is again expected to foster the growth of the market. Key players operating in the global recombinant human endostatin market include Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG. A growing number of research & development activities to recognize potential applications of recombinant human endostatin is expected to foster the growth of the reco...